

# REGENERON

## Media Statement

---

**October 20, 2025**

### **Regeneron Provides Update on Patent Litigation Against Celltrion**

Regeneron has reached resolution of our patent infringement litigation related to the Celltrion EYLEA® (aflibercept) Injection 2 mg biosimilar product. The settlement allows Celltrion to launch its biosimilar product in the U.S. on December 31, 2026. All intellectual property-related litigation in the U.S. with Celltrion will be dismissed. The financial and other terms of the agreement are confidential.

Regeneron has invested many years of effort into its design and development of EYLEA and remains committed to actively enforcing its intellectual property rights.

#### **About Regeneron**

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit [www.Regeneron.com](http://www.Regeneron.com) or follow Regeneron on [LinkedIn](#), [Instagram](#), [Facebook](#) or [X](#).

#### **Forward-Looking Statements and Use of Digital Media**

*This statement includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include,*

*among others, risks associated with intellectual property of Regeneron or other parties and pending or future litigation relating thereto, the ultimate outcome of any such litigation or related proceedings, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2024 and its Form 10-Q for the quarterly period ended June 30, 2025. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.*

*Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (<https://investor.regeneron.com>) and its LinkedIn page (<https://www.linkedin.com/company/regeneron-pharmaceuticals>).*

**Contacts:**

**Media Relations**

Mary Heather

Tel: +1 914-847-8650

[mary.heather@regeneron.com](mailto:mary.heather@regeneron.com)

**Investor Relations**

Mark Hudson

Tel: +1 914-847-3482

[mark.hudson@regeneron.com](mailto:mark.hudson@regeneron.com)